의약품, 바이오테크놀러지, 진단 관련 사업자의 합작투자 : 제휴 조건, 합의 내용
Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021
상품코드 : 315594
리서치사 : Current Partnering, a division of Wildwood Ventures Limited
발행일 : 2021년 04월
페이지 정보 : 영문 350+ Pages
US $ 3,495 ₩ 3,959,000
PDF (Single User License)
US $ 5,245 ₩ 5,941,000
PDF (Multi User License - 2 to 5 Users)
US $ 10,495 ₩ 11,888,000
PDF (Single Site License - 6+ Users)
US $ 17,495 ₩ 19,818,000
PDF (Global License)


한글목차

의약품, 바이오테크놀러지, 진단 관련 사업자의 합작투자(Joint Venture) 제휴 계약 동향을 조사했으며, 합작투자 제휴의 구조, 성공요인, 사례 연구, 최근 제휴 계약의 동향, 개발 단계·치료 분야·기술 등 각종 부문별 내역, 주요 대형 계약, 제휴 계약에 적극적인 기업의 개요 등을 정리하여 전해드립니다.

개요

제1장 서론

제2장 합작투자 제휴의 동향

제3장 합작투자 계약의 구조 : 개요

제4장 주요 계약

제5장 주요 25사

제6장 계약 디렉토리

부록

KSA 19.07.11

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

영문 목차

영문목차

The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the joint venture partnering agreements entered into by the worlds leading healthcare companies.

The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies.

This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2014.

There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.

Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.

Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.

The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all joint venture deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of joint venture dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in joint venture as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of joint venture deals. The chapter includes numerous case studies to enable understanding of joint venture deals.

Chapter 4 provides a review of the leading Joint venture deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active Joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of Joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2014 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Joint venture deal.

The appendices to the report includes a comprehensive listing of all Joint venture deals announced since 2014. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in Joint venture dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances.

Key benefits

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 provides the reader with the following key benefits:

Report scope

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 includes:

In Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 available deals and contracts are listed by:

The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive access to available contract documents for joint venture deals. Analyzing actual contract agreements allows assessment of the following:

Benefits

Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 provides the reader with the following key benefits:

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in joint venture partnerships

Chapter 3 - Overview of joint venture deal structure

Chapter 4 - Leading joint venture deals

Chapter 5 - Top 25 most active active joint venture dealmakers

Chapter 6 - Joint venture deals including contracts directory

Appendices

TABLE OF FIGURES

(주)글로벌인포메이션 02-2025-2992 koreainfo@gii.co.jp
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기